This article is more than 5 years old. Information may no longer be current.

Apellis begins phase 3 clinical program for geographic atrophy treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A two-trial phase 3 clinical program for APL-2 for geographic atrophy has begun with the first patient enrolled in the DERBY trial and the first patient dosed in the OAKS trial, Apellis Pharmaceuticals announced in a press release.

The two-trial prospective, international, multicenter, randomized, double-masked, sham-injection controlled program will include 600 patients with geographic atrophy and assess the efficacy and safety of multiple intravitreal injections of APL-2, the release said.

“Dosing the first patient in our phase 3 program in geographic atrophy is an exciting milestone for Apellis, physicians and most importantly patients suffering from GA,” Cedric Francois, MD, PhD, co-founder and CEO of Apellis, said in the release. “APL-2 offers hope for patients currently without an approved treatment option.”

APL-2, which received fast track designation from the FDA, previously met its primary endpoint of a reduction in geographic atrophy lesion growth after 12 months in the phase 2 FILLY trial.